Predicting motor, cognitive & functional impairment in Parkinson's
- PMID: 31402628
- PMCID: PMC6689691
- DOI: 10.1002/acn3.50853
Predicting motor, cognitive & functional impairment in Parkinson's
Abstract
Objective: We recently demonstrated that 998 features derived from a simple 7-minute smartphone test could distinguish between controls, people with Parkinson's and people with idiopathic Rapid Eye Movement sleep behavior disorder, with mean sensitivity/specificity values of 84.6-91.9%. Here, we investigate whether the same smartphone features can be used to predict future clinically relevant outcomes in early Parkinson's.
Methods: A total of 237 participants with Parkinson's (mean (SD) disease duration 3.5 (2.2) years) in the Oxford Discovery cohort performed smartphone tests in clinic and at home. Each test assessed voice, balance, gait, reaction time, dexterity, rest, and postural tremor. In addition, standard motor, cognitive and functional assessments and questionnaires were administered in clinic. Machine learning algorithms were trained to predict the onset of clinical outcomes provided at the next 18-month follow-up visit using baseline smartphone recordings alone. The accuracy of model predictions was assessed using 10-fold and subject-wise cross validation schemes.
Results: Baseline smartphone tests predicted the new onset of falls, freezing, postural instability, cognitive impairment, and functional impairment at 18 months. For all outcome predictions AUC values were greater than 0.90 for 10-fold cross validation using all smartphone features. Using only the 30 most salient features, AUC values greater than 0.75 were obtained.
Interpretation: We demonstrate the ability to predict key future clinical outcomes using a simple smartphone test. This work has the potential to introduce individualized predictions to routine care, helping to target interventions to those most likely to benefit, with the aim of improving their outcome.
© 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
Conflict of interest statement
Christine Lo: Oxford Biomedical Research Centre; Siddharth Arora: University of Oxford; Fahd Baig: Oxford Discovery; Michael Lawton: Oxford Discovery; Claire El Mouden: Oxford Biomedical Research Centre; Tom Barber: Wellcome Trust Doctoral Training Fellowship; Claudio Ruffman: None; Johannes Klein: Oxford Health NIHR Biomedical Research Centre; Peter Brown: Medical Research Council (MC_UU_12024/1); Yoav Ben‐Shlomo: University of Bristol; Maarten de Vos: Oxford BRC, EPSRC, BBSRC, Roche; Michele Hu: Parkinson's UK Monument Discovery Award, Oxford BRC, University of Oxford, National Institute for Health Research, Michael J Fox Foundation, H2020 European Union, GE Healthcare, PSP Association. Consultant for Biogen and Roche Advisory Boards. Parkinson's UK: Targeting the pathological pathways to Parkinson's and Understanding the early pathological pathways in Parkinson's Disease
Figures



References
-
- Horváth K, Aschermann Z, Ács P, et al. Minimal clinically important difference on the motor examination part of MDS‐UPDRS. Parkinsonism Relat Disord 2015;21:1421–1426. - PubMed
-
- Rascol O, Fitzer‐Attas CJ, Hauser R, et al. A double‐blind, delayed‐start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post‐hoc analyses of the need for additional therapies, changes in UPDRS scores, and non‐motor outcomes. Lancet Neurol 2011;10:415–423. - PubMed
-
- Post B, Merkus MP, de Haan RJ, et al. Prognostic factors for the progression of Parkinson's disease: a systematic review. Movement Disord 2007;22:1839–1851. - PubMed
-
- Ehgoetz Martens KA, Lukasik EL, Georgiades MJ, et al. Predicting the onset of freezing of gait: A longitudinal study. Mov Disord 2018;33:128–35. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical